Close
FINDING CURES TOGETHER<sup>SM</sup>

Translational Cancer Research for Basic Scientists Workshop

Program 


Sunday, Nov. 17 

Registration
2-7:30 p.m.


Welcome and Introductions: Workshop Course Directors and Participants
4-4:30 p.m.

Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Workshop Alumni Panel- From Bench to Bedside: How to Translate a Basic Science Study to the Clinic
4:30-6 p.m.

Abena Agyeman, PhD, U.S. Food and Drug Administration, Silver Spring, Maryland
Hua Fang, PhD, AbbVie Inc., Redwood City, California
Aime Franco, PhD, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Daotai Nie, PhD, Southern Illinois University School of Medicine, Springfield, Illinois


Opening Keynote Presentation
6-7:30 p.m.

New insights in technology in the future of translation
Phillip A. Sharp, PhD, David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts


Opening Reception and Dinner
7:30-9 p.m.


Top of page



Monday, Nov. 18 

Continental Breakfast
7-8 a.m.


Pre-Test (required)
8-8:30 a.m.


The Environment of Clinical Investigations
8:30-11 a.m.

Clinical research: An overview    
Peter C. Adamson, MD, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Ethical conduct of translational research 
Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, New York, New York

Protection of human research participants
Alison Bateman-House, PhD, MPH, MA, New York University School of Medicine, New York, New York

Why quantitative reasoning is important in translational cancer research
Mimi Kim, ScD, Albert Einstein College of Medicine, New York, New York

Panel Discussion


Buffet Lunch
11 a.m.-12:15 p.m.


Offsite Laboratory Visits
12:30-5 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided
.

Surgical Pathology Laboratory tour and discussion
Diagnostic Radiology Laboratory tour and discussion
*Workshop attendees visit both laboratories during the time allotted.


Group Buffet Dinner
5-6 p.m.


Study Design Track Meeting (Groups A and B)
Those who are in the Project Meeting will not participate in the One-on-One Meetings.
5:30-7 p.m.


One-on-One Meetings ("Office Hours")
6-7 p.m.


Keynote Presenation
7-8 p.m.

Unleashing the Power of Immune System - Focus on Translational Immunology
Carl H. June, MD, University of Pennsylvania, Philadelphia, Pennsylvania


Top of page



Tuesday, Nov. 19 

Continental Breakfast
7-8 a.m.

Introduction to Cancer Medicine and Diagnostics
8-10:45 a.m.

Overview: An introduction to clinical cancer medicine
Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Overview of pathology and molecular tools in diagnostics
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts

Cancer imaging: The role of imaging in oncology
Lawrence H. Schwartz, MD, Columbia University Medical Center, New York, New York

EGFR mutant lung cancer: From clinic to bench to back to clinic
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion


Break
11-11:15 a.m.


Lunch and Human Subject Research Protections Session 
11:15 a.m.-2 p.m.

Participants will gain insights into the role of the Institutional Review Board (IRB) in the ethical and regulatory oversight of human research and will explore issues of the protection of human subjects that are at the heart of translational research.  Small groups of participants will serve as mock IRBs and will apply the ethical principles of the Belmont Report and the federal regulatory criteria to specific research projects and informed consent documents.

Overview of IRB
Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Alison Bateman-House, PhD, MPH, MA, New York University School of Medicine, New York, New York

Human Subject Research Protections interactive session
Yvonne Higgins, WIRB-Copernicus Group, Cary, North Carolina

Discussion and Questions on IRB Session


Special Presentation
2-2:30 p.m.

Development of biomarker-based combinatorial strategies to address PARP inhibitor resistance
Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Orientation/Questions for Cancer Patient Clinic Visits
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Free Time
2:30-4 p.m.


Study Design Track Meeting
3-4:30 p.m.


One-on-One Meetings ("Office Hours")
4-5:30 p.m.


Group Buffet Dinner
5:30-6:30 p.m.


Small Group Discussion Sessions with Clinician and Patient
6:30-8 p.m.

Each small group consists of a clinician, a patient, and approximately 10-15 workshop attendees. This provides a comfortable environment and encourages interaction. We ask doctors to share their perspectives as clinicians and researchers, and patients to speak about whatever they feel most comfortable sharing regarding their experiences as patients/clinical trial participants.


Top of page


Wednesday, Nov. 20 

Continental Breakfast
7:30-8:30 a.m.


Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.


Buffet Lunch
12-1 p.m.


The Research and Development Process
1-3:45 p.m.  

Taxol, tubulin, and tumors: A story of drug development
Susan Band Horwitz, PhD, Albert Einstein Medical College, Bronx, New York

Targeting tumor associated macrophages for anti-cancer therapy
Jennifer Guerriero, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Translational cancer research in drug development
Ellen Filvaroff, PhD, Celgene Corporation, San Francisco, California

Chance favors the prepared mind in oncology drug development
Eric H. Rubin, MD, Merck & Co., Inc., North Wales, Pennsylvania

Panel Discussion and Questions: Research and Development


Break
3:45-4:15 p.m.


Interactive Lab and Demo-cBioPortal: Cancer Genomics and Translational Research
4:15-6:15 p.m.

Introduction to cBioPortal for cancer genomics
Tali Mazor, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Advanced cBioPortal for cancer genomics
Ino de Bruijn, MS, Memorial Sloan Kettering Cancer Center, New York, New York


Evening on Own
6:15 p.m.-


Top of page



Thursday, Nov. 21 

Continental Breakfast
7:30-8:30 a.m.


Offsite Patient Clinic Visits

8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.


Buffet Lunch
12-1:30 p.m.


Targeted Medicine
1:30-3:30 p.m.

Genomic analysis of cell-free plasma DNA
Ryan B. Corcoran MD, PhD, Massachusetts General Hospital, Boston, Massachusetts

Regulatory science: What are the issues?
Chana Weinstock, MD, Food and Drug Administration, Silver Spring, Maryland

Biomarkers and molecular diagnostics: Matching patients to therapeutic options
Maureen Cronin, PhD, Celgene Corporation, San Francisco, California

Panel Discussion on Targeted Medicine


Break
3:30-4 p.m.


Entrepreneurship in Translational Research and Careers in Industry (Panel Discussion)
Moderator: George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
4-5:30 p.m.

Tarangini Deshpande, PhD, NuMedii, San Mateo, California
Uciane Scarlett, Oxford Sciences Innovation, Oxford, United Kingdom
Maureen T. Cronin, PhD, HTG Molecular Diagnostics, Inc. Tucson, Arizona


Dinner
5:30-6:30 p.m.


How Treatment Decisions Are Made
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Adrián Mariño Enríquez, MD, PhD, Brigham and Women's Hospital, Boston, Massachusetts
6:30-7:30 p.m.


Top of page


Friday, Nov. 22 

Continental Breakfast
7-8 a.m.


Translating Differently
8-10:45 a.m.

Precision Breast Cancer Care: Translation for “All of Us”
Olufunmilayo I. Olopade, MD, University of Chicago Medical Center, Chicago, Illinois

Precision head and neck cancer medicine
Jennifer R. Grandis, MD, University of California, San Francisco, California

Targeting DUBs for cancer therapy
Sara J. Buhrlage, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

AACR’s Project GENIE: Genomics to phenomics
Deborah Schrag, MPH/MD, Dana-Farber Cancer Institute, Boston, Massachusetts


Closing Keynote Presentation
10:45-11:45 a.m.

ER Stress Reprograms the Tumor Microenvironment
Laurie H. Glimcher, MD, Dana-Farber Cancer Institute, Boston, Massachusetts


Closing Remarks
11:45 a.m.-12 p.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York


Post-Test / Evaluation
12-12:30 p.m.


Attendee Departure
12:30 p.m.


Top of page